Clinical Trial Update: mRNA Expression as a Biomarker of Omalizumab Response [Phase 4]

View source ↗

Summary

A Phase 4 study investigates mRNA expression as a biomarker to predict omalizumab response in asthma. The trial status is currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Instituto de Investigação em Imunologia | Conditions: Asthma | Phase 4 | Status: UNKNOWN